Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:10:55.144Z.
Calculation as of: 2026-10-06T14:10:55.144Z.
Quote observation: 2026-10-06T14:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Anteris Technologies Global Corp.
Market Cap
$716.11M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$715.49M
Operating Cash Flow Yield
46.11%
TTM Avg
23.51%
3Y Avg
20.54%
5Y Avg
18.34%
Market Cap
$715.02M
Operating Cash Flow Yield
N/A
TTM Avg
23.08%
3Y Avg
23.11%
5Y Avg
23.11%
Market Cap
$719.62M
Operating Cash Flow Yield
N/A
TTM Avg
5.57%
3Y Avg
5.48%
5Y Avg
5.48%
Market Cap
$740.03M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$684.68M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$745.42M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$674.39M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$668.31M
Operating Cash Flow Yield
6.91%
TTM Avg
9.30%
3Y Avg
5.99%
5Y Avg
5.99%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $716.11M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 46.11% | 23.51% | 20.54% | 18.34% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $715.02M | N/A | 23.08% | 23.11% | 23.11% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.62M | N/A | 5.57% | 5.48% | 5.48% |
| Candel Therapeutics, Inc. (CADL)vs › | $740.03M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $684.68M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $674.39M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.31M | 6.91% | 9.30% | 5.99% | 5.99% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
